A Phase 2 interventional study of BLU-5937 and Placebo in Chronic Refractory Cough, sponsored by Bellus Health Inc. - a GSK company. Terminated at 16 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-08-03.
Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Chronic Cough · United States.
Among the 44 studies in Chronic Cough with a site in United States, this one is the 14th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2019, is one of 16 in phase 2, and was the 16th registered.
142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.
Browse Chronic Cough studies →9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–80
University of Montana · Sites in United States
Ages 18–99
Hyfe Inc · Sites in United States
Ages 21+
Medical University of South Carolina · Sites in United States
Ages 18+
University of Montana · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 50 across the 37 interventional studies, 35 across the 7 observational. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bellus Health Inc. - a GSK company, one of the names counted as GlaxoSmithKline. Under that name alone:
Bellus Health Inc. - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 4 (36%) have results posted.
GlaxoSmithKline has 9 studies filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
3 of the studies in Chronic Cough with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05110144Mayo ClinicEfficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough | 2026-12 |
| NCT05273190University of MinnesotaStimulation of the Larynx to Treat Unexplained Chronic Cough | 2027-06-01 |
| NCT06634823Medical University of South CarolinaEfficacy of Intramuscular Steroid Injection for Chronic Cough. | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Chronic Cough with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough
This study will have two 16-day treatment periods (four escalating doses or matching placebo at four days interval) separated by a 10 to 14-day washout period. There will be a 14-day follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID
Drug: BLU-5937
Randomized crossover design of matching placebo tablets to be administered orally BID
Drug: Placebo
Four escalating doses of BLU-5937 administered BID over the course of the study
Matching placebo for BLU-5937
Change in Awake Objective Cough Frequency on Log-transformed Scale
Change in awake cough frequency (average hourly cough frequency while the subject is awake ) evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected
Time frame: Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses
Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = 20 Coughs/Hour at Baseline
Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency \> or = 20 coughs/hour at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected
Time frame: Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12, 16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses
Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = Median (32.4 Coughs/Hour) at Baseline
Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency \> or = median (32.4 coughs/hour) at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected
Time frame: Period 1: baseline (Day 0) and 24 hours after Day 4, 8, 12,16 doses ; Period 2: baseline (Day 30) and 24 hours after Day 34, 38, 42, 46 doses
Participants were recruited at 16 clinical trial sites in the United-Kingdom and in United States.
| Milestone | BLU-5937 > Placebo | Placebo > BLU-5937 |
|---|---|---|
| Started | 33 | 35 |
| Completed | 26 | 28 |
| Not completed | 7 | 7 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Study terminated by sponsor | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Milestone | BLU-5937 > Placebo | Placebo > BLU-5937 |
|---|---|---|
| Started | 26 | 28 |
| Completed | 25 | 27 |
| Not completed | 1 | 1 |
| Withdrew: Study terminated by sponsor | 1 | 1 |
Change in awake cough frequency (average hourly cough frequency while the subject is awake ) evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected
| Log coughs/hour | BLU-5937 - 25 mg | Placebo Comparator - 25 mg | BLU-5937 - 50 mg | Placebo Comparator - 50 mg | BLU-5937 - 100 mg | Placebo Comparator - 100 mg | BLU-5937 - 200 mg | Placebo Comparator - 200 mg |
|---|---|---|---|---|---|---|---|---|
| Change in Awake Objective Cough Frequency on Log-transformed Scale | -0.19 (-0.29 to -0.08) | -0.07 (-0.19 to 0.05) | -0.20 (-0.32 to -0.08) | -0.14 (-0.26 to -0.01) | -0.25 (-0.40 to -0.09) | -0.17 (-0.30 to -0.04) | -0.33 (-0.49 to -0.17) | -0.14 (-0.29 to 0.00) |
Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency \> or = 20 coughs/hour at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected
| Log coughs/hour | BLU-5937 - 25 mg | Placebo Comparator - 25 mg | BLU-5937 - 50 mg | Placebo Comparator - 50 mg | BLU-5937 - 100 mg | Placebo Comparator - 100 mg | BLU-5937 - 200 mg | Placebo Comparator - 200 mg |
|---|---|---|---|---|---|---|---|---|
| Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = 20 Coughs/Hour at Baseline | -0.23 (-0.34 to -0.11) | 0.00 (-0.09 to 0.10) | -0.29 (-0.42 to -0.15) | -0.09 (-0.21 to 0.03) | -0.33 (-0.51 to -0.16) | -0.12 (-0.25 to 0.01) | -0.41 (-0.58 to -0.24) | -0.09 (-0.23 to 0.05) |
Change in awake cough frequency (average hourly cough frequency while the subject is awake) in the a pre-specified subgroup of participants with awake cough frequency \> or = median (32.4 coughs/hour) at baseline evaluated using the VitaloJAK cough monitor with 24-hour sound recordings collected
| Log coughs/hour | BLU-5937 - 25 mg | Placebo Comparator - 25 mg | BLU-5937 - 50 mg | Placebo Comparator - 50 mg | BLU-5937 - 100 mg | Placebo Comparator - 100 mg | BLU-5937 - 200 mg | Placebo Comparator - 200 mg |
|---|---|---|---|---|---|---|---|---|
| Change in Awake Cough Frequency on Log-transformed Scale in the Subgroup of Participants With Awake Cough Frequency > or = Median (32.4 Coughs/Hour) at Baseline | -0.31 (-0.45 to -0.18) | 0.02 (-0.11 to 0.15) | -0.42 (-0.55 to -0.28) | -0.08 (-0.22 to 0.05) | -0.44 (-0.60 to -0.27) | -0.09 (-0.24 to 0.06) | -0.49 (-0.68 to -0.31) | -0.10 (-0.24 to 0.03) |
Collected over All-cause mortality and Adverse Event data collection is up to 11 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BLU-5937 - 25 mg | 0/61 (0%) | 0/61 (0%) | 10/61 (16.4%) |
| BLU-5937 - 50 mg | 0/61 (0%) | 0/61 (0%) | 14/61 (23%) |
| BLU-5937 - 100 mg | 0/60 (0%) | 0/60 (0%) | 15/60 (25%) |
| BLU-5937 - 200 mg | 0/58 (0%) | 0/58 (0%) | 10/58 (17.2%) |
| Placebo | 0/61 (0%) | 1/61 (1.6%) | 19/61 (31.1%) |
| Event | BLU-5937 - 25 mg | BLU-5937 - 50 mg | BLU-5937 - 100 mg | BLU-5937 - 200 mg | Placebo |
|---|---|---|---|---|---|
| colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | — | — | — | — | 1/61 |
| Event | BLU-5937 - 25 mg | BLU-5937 - 50 mg | BLU-5937 - 100 mg | BLU-5937 - 200 mg | Placebo |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/61 | 2/61 | 4/60 | 3/58 | 7/61 |
| Back painMusculoskeletal and connective tissue disorders | 2/61 | 3/61 | 2/60 | 1/58 | 6/61 |
| DysgeusiaNervous system disorders | 3/61 | 5/61 | 5/60 | 4/58 | 2/61 |
| Upper respiratory tract infectionInfections and infestations | 2/61 | 4/61 | 4/60 | 3/58 | 3/61 |
| DizzinessNervous system disorders | 3/61 | 4/61 | 3/60 | 2/58 | 2/61 |
| DiarrhoeaGastrointestinal disorders | 1/61 | 1/61 | 1/60 | 0/58 | 3/61 |
The baseline analysis population consisted of all randomized participants who have received at least 1 dose of study drug.
| Age, Continuous(years) | BLU-5937 > Placebo | Placebo > BLU-5937 | Total |
|---|---|---|---|
| Mean | 64.3 ± 11.49 | 63.7 ± 9.70 | 64.0 ± 10.53 |
| Sex: Female, Male(Participants) | BLU-5937 > Placebo | Placebo > BLU-5937 | Total |
|---|---|---|---|
| Female | 28 | 30 | 58 |
| Male | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | BLU-5937 > Placebo | Placebo > BLU-5937 | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 29 | 34 | 63 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | BLU-5937 > Placebo | Placebo > BLU-5937 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 33 | 33 | 66 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2019 to primary completion in Apr 2020, 9 months.
Results were first posted in Aug 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BLU-5937
Bellus Health Inc. - a GSK company →